Director Christopher D. Maggiore reported a purchase of 1,766 shares of Zivo Bioscience Inc. (NASDAQ: ZIVO) common stock on January 14, 2026. The transaction was executed at $8.49 per share, resulting in a total outlay of $14,993.
Following the acquisition, Maggiore's direct ownership in Zivo Bioscience stands at 519,292 shares. The firm carries a market capitalization of $38.52 million.
Price movement and market context
According to InvestingPro data cited in the filing, ZIVO's share price has climbed 16.77% over the past week. The same source indicates the stock is trading close to its Fair Value. Analysts referenced by InvestingPro expect sales growth for the company during the current year, even though Zivo Bioscience has not been profitable over the last twelve months.
Those points - the recent week-long price appreciation, the Fair Value assessment and the outlook for sales growth despite recent unprofitability - are the core facts presented alongside Maggiore's disclosed purchase.
What the filing shows
- The director purchased 1,766 common shares on January 14, 2026.
- Purchase price was $8.49 per share, totaling $14,993.
- After the trade, direct holdings total 519,292 shares.
- Zivo Bioscience's market capitalization is stated as $38.52 million.
- InvestingPro data reports a 16.77% share price increase over the prior week and notes the company is trading near its Fair Value, with analysts forecasting sales growth in the current year despite a lack of profitability in the last twelve months.
Limitations and scope
The disclosure provides transaction details and selected InvestingPro metrics and analyst expectations. It does not provide additional context on the reasons for the director's purchase, the drivers of the recent share-price move, or further company-specific financial details beyond the profitability statement and the market-cap figure.